Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic myeloid leukemia patients at presentation at a tertiary care teaching hospital in Addis Ababa, Ethiopia: a cross-sectional study.
Humans
Male
Cross-Sectional Studies
Female
Ethiopia
/ epidemiology
Adult
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ genetics
Hospitals, Teaching
Middle Aged
Young Adult
Adolescent
Tertiary Care Centers
/ statistics & numerical data
Aged
Cytogenetic Analysis
Fusion Proteins, bcr-abl
/ genetics
Tertiary Healthcare
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
26 Apr 2024
26 Apr 2024
Historique:
received:
23
01
2024
accepted:
17
04
2024
medline:
26
4
2024
pubmed:
26
4
2024
entrez:
25
4
2024
Statut:
epublish
Résumé
In low-income countries there is insufficient evidence on hematological, clinical, cytogenetic and molecular profiles among new CML patients. Therefore, we performed this study among newly confirmed CML patients at Tikur Anbesa Specialized Hospital (TASH), Ethiopia. To determine the hematological, clinical, cytogenetic and molecular profiles of confirmed CML patients at tertiary care teaching hospital in Addis Ababa, Ethiopia. A facility-based cross-sectional study was conducted to evaluate hematological, clinical, cytogenetic and molecular profiles of confirmed CML patients at TASH from August 2021 to December 2022. A structured questionnaire was used to collect the patients' sociodemographic information, medical history and physical examination, and blood samples were also collected for hematological, cytogenetic and molecular tests. Descriptive statistics were used to analyze the sociodemographic, hematological, clinical, cytogenetic and molecular profiles of the study participants. A total of 251 confirmed new CML patients were recruited for the study. The majority of patients were male (151 [60.2%]; chronic (CP) CML, 213 [84.7%]; and had a median age of 36 years. The median (IQR) WBC, RBC, HGB and PLT counts were 217.7 (155.62-307.4) x10 During presentation, most CML patients presented with hyperleukocytosis, neutrophilia and anemia at TASH, Addis Ababa. Fatigue, abdominal pain, splenomegaly and weight loss were the most common signs and symptoms observed in the CML patients. Most CML patients were diagnosed by FISH, and p120 was detected in all CML patients diagnosed by PCR. The majority of CML patients arrive at referral center with advanced signs and symptoms, so better to decentralize the service to peripheral health facilities.
Sections du résumé
BACKGROUND
BACKGROUND
In low-income countries there is insufficient evidence on hematological, clinical, cytogenetic and molecular profiles among new CML patients. Therefore, we performed this study among newly confirmed CML patients at Tikur Anbesa Specialized Hospital (TASH), Ethiopia.
OBJECTIVE
OBJECTIVE
To determine the hematological, clinical, cytogenetic and molecular profiles of confirmed CML patients at tertiary care teaching hospital in Addis Ababa, Ethiopia.
METHODS
METHODS
A facility-based cross-sectional study was conducted to evaluate hematological, clinical, cytogenetic and molecular profiles of confirmed CML patients at TASH from August 2021 to December 2022. A structured questionnaire was used to collect the patients' sociodemographic information, medical history and physical examination, and blood samples were also collected for hematological, cytogenetic and molecular tests. Descriptive statistics were used to analyze the sociodemographic, hematological, clinical, cytogenetic and molecular profiles of the study participants.
RESULTS
RESULTS
A total of 251 confirmed new CML patients were recruited for the study. The majority of patients were male (151 [60.2%]; chronic (CP) CML, 213 [84.7%]; and had a median age of 36 years. The median (IQR) WBC, RBC, HGB and PLT counts were 217.7 (155.62-307.4) x10
CONCLUSION
CONCLUSIONS
During presentation, most CML patients presented with hyperleukocytosis, neutrophilia and anemia at TASH, Addis Ababa. Fatigue, abdominal pain, splenomegaly and weight loss were the most common signs and symptoms observed in the CML patients. Most CML patients were diagnosed by FISH, and p120 was detected in all CML patients diagnosed by PCR. The majority of CML patients arrive at referral center with advanced signs and symptoms, so better to decentralize the service to peripheral health facilities.
Identifiants
pubmed: 38664756
doi: 10.1186/s12885-024-12282-x
pii: 10.1186/s12885-024-12282-x
doi:
Substances chimiques
Fusion Proteins, bcr-abl
EC 2.7.10.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
530Informations de copyright
© 2024. The Author(s).
Références
Ngono AP, Tipane PA, Raoul S, Njonnou S, Timnou AT et al. Hematobiological Profile of patients with chronic myeloid leukemia at the diagnosis in Yaoundé: a cross-sectional study. Open J Blood Dis. 2020; 110–23.
Ogunleye F, Ibrahim M, Allen E, Brennan N, Huang J, Yu Z, Huben M, Jaiyesimi I. BCR-ABL testing by polymerase chain reaction in patients with neutrophilia: the William Beaumont Hospital experience and the case for rational laboratory test requests. J Oncol Pract. 2016;12(12):e1001–5.
doi: 10.1200/JOP.2016.014449
pubmed: 27624943
Tadesse F, Asres G, Abubeker A, Gebremedhin A, Radich J. Spectrum of BCR-ABL mutations and treatment outcomes in Ethiopian Imatinib-resistant patients with chronic myeloid leukemia original reports abstract. JCO Glob Oncol. 2021; 1187–93.
Smith G, Apperley J, Milojkovic D, Cross NCP, Foroni L, Byrne J, et al. A British Society for Hematology Guideline on the diagnosis and management of chronic myeloid leukemia. BJH. 2020;191:171–93.
doi: 10.1111/bjh.16971
pubmed: 32734668
Minciacchi VR, Kumar R, Krause DS. Chronic myeloid leukemia: a model disease of the past, present and future. Cells. 2021;10(1):1–23.
doi: 10.3390/cells10010117
Wiyono MR, Ugroseno S, Bintoro Y, Hernaningsih Y. Characteristic of chronic myelogenous leukemia patients at the Polyclinic of Oncology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia in 2017. MBIOMJ. 2020;30(1):27–33.
doi: 10.20473/mbiom.v30i1.2020.27-33
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.
doi: 10.1182/blood-2016-03-643544
pubmed: 27069254
Jabbour E, Kantarjian H, Chronic C, Leukemia M, Found B, To Q, About A, Myeloid C. Chronic Myeloid Leukemia Early Detection, Diagnosis, and Staging Can Chronic Myeloid Leukemia Be Found Early? Signs and Symptoms of Chronic Myeloid Leukemia. Cancer: 1–13.
Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic myeloid leukemia, version 1.2019. JNCCN J Natl Compr Cancer Netw. 2018;16(9):1108–35.
doi: 10.6004/jnccn.2018.0071
Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and treatment of chronic myeloid leukemia in 2015. InMayo Clinic Proceedings. 2015; 90 (10): 1440–1454.
Bonifacio M, Stagno F, Scaffidi L, Krampera M, Di Raimondo F. Management of chronic myeloid leukemia in advanced phase. Front Oncol. 2019;9:1132.
doi: 10.3389/fonc.2019.01132
pubmed: 31709190
pmcid: 6823861
Hochhaus A, Breccia M, Saglio G, García-Gutiérrez V, Réa D, Janssen J, Apperley J. Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34(6):1495–502.
doi: 10.1038/s41375-020-0842-9
pubmed: 32366938
pmcid: 7266739
García-Gutiérrez V, Breccia M, Jabbour E, Mauro M, Cortes JE. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022;15(1):1–5.
doi: 10.1186/s13045-022-01309-0
Singh A, Kulshrestha AR, Singh SK, Kulshrestha MR. To study the Clinical and Hematological Profile of CML patients and to compare the hematological response of Imatinib and Hydroxyurea in different subsets of CML patients. Saudi J Pathol Microbiol. 2019;3362:127–33.
Mulu Fentie A, Tadesse F, Engidawork E, Gebremedhin A. Prevalence and determinants of nonadherence to Imatinib in the first 3-months treatment among newly diagnosed ethiopians with chronic myeloid leukemia. PLoS ONE. 2019;14(3):e0213557.
doi: 10.1371/journal.pone.0213557
pubmed: 30845227
pmcid: 6405163
Chang F, Qazi RA, Khan M, Baloch S, Sahito MM, Mir A. Clinico hematological profile and phase distribution of chronic myeloid leukemia. Biol Med. 2015;7(5):5–8.
doi: 10.4172/0974-8369.1000257
Sultan S, Jaffri SA, Zeeshan R, Irfan SM. Chronic myeloid leukemia: Clinico- Hematological Profile from Southern Pakistan.; 30(46):34–8. https://doi.org/10.53350/pjmhs2115113047 .
Al-abady I. Clinico-Hematological Profile in patients with chronic myeloid leukemia. Annals Coll Med Mosul. 2021;43(1):1–9.
doi: 10.33899/mmed.2020.128677.1054
Kumar S, Gupta VK, Bharti A, Meena LP, Gupta V, Shukla J. A study to determine the clinical, hematological, cytogenetic, and molecular profile in CML patient in and around Eastern UP, India. J Family Med Prim Care. 2019;8:2450–5.
doi: 10.4103/jfmpc.jfmpc_307_19
pubmed: 31463275
pmcid: 6691447
Srinivas KG, Patil S, Shashidhara S. Epidemiological and clinical profile of patients with chronic myeloid leukemia at health-care global, Bangalore institute of oncology. Indian J Med Paediatr Oncol. 2013;34(3):211–2.
doi: 10.4103/0971-5851.123746
pubmed: 24516314
pmcid: 3902629
Sinha R, Jamal I, Priyamvada PP. Clinico-hematological Profile of Chronic myeloid leukemia: an institutional based study from Bihar. Age NJLM. 2019;28(7):43–6.
Henke O, Mapendo PJ, Mkwizu EW, le Coutre P. Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukemia patients treated with Imatinib and barriers to access treatment. Ecancermedicalscience. 2020; 14.
Tebuka E, Makubi A, Maunda K. Complete hematological response to imatinib in chronic myeloid leukemia patients attending the Ocean Road Cancer Institute in Tanzania. Tanzan J Health Res 2016; 18(4).
Genthon A, Nicolini FE, Huguet F, Colin-Gil C, Berger M, Saugues S, et al. Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib. Oncotarget. 2020;11(26):2560–70.
doi: 10.18632/oncotarget.27652
pubmed: 32655840
pmcid: 7335668
Molica M, Abruzzese E, Breccia M. Prognostic significance of transcript-type BCR-ABL1 in chronic myeloid leukemia. Mediterr J Hematol Infect Dis. 2020;12(1):e2020062.
doi: 10.4084/mjhid.2020.062
pubmed: 32952973
pmcid: 7485470